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 Abstract 
  The development of well-tolerated and effective therapies that target the pathogenesis of 
membranous nephropathy (MN) would be useful. Our objective was to evaluate the efficacy of 
rituximab in MN. We analyzed the outcome of 28 patients treated with rituximab for idiopathic 
MN. Anti-PLA  2  R antibodies in serum and PLA  2  R antigen in kidney biopsy were assessed in 10 
and 9 patients, respectively. Proteinuria was significantly decreased by 56, 62 and 87% at 3, 6 
and 12 months, respectively. At 6 months, 2 patients achieved complete remission (CR) and 12 
partial remission (PR; overall renal response, 50%). At 12 months (n = 23), CR was achieved in 6 
patients and PR in 13 patients (overall renal response, 82.6%). Three patients suffered a relapse 
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of nephrotic proteinuria 27–50 months after treatment. Univariate analysis suggested that the 
degree of renal failure (MDRD estimated glomerular filtration rate   ! 45/ml/min/1.73  m 2  ) is an 
independent factor that predicts lack of response to rituximab. Anti-PLA  2 R antibodies were de-
tected in the serum of 10 patients, and PLA  2  R antigen in immune deposits in 8 of 9 patients. 
Antibodies became negative in all 5 responsive patients with available follow-up sera. In this 
retrospective study, a high rate of remission was achieved 12 months after treatment.
  Copyright © 2011 S. Karger AG, Basel 
  Introduction 
  Membranous nephropathy (MN) is an antibody-mediated disease induced by deposits 
of immunoglobulins and complement components on the subepithelial layer of the glomer-
ular capillary wall. It is the most common cause of the nephrotic syndrome (NS) in white 
adults, accounting for 7–20% of NS   [1, 2]  . In 75% of cases, the etiology of MN is unknown 
and the disease is referred to as idiopathic. In 25% of cases, MN is associated with autoim-
mune disease (e.g. systemic lupus erythematosus), exposure to drugs (e.g. nonsteroidal anti-
inflammatory drugs), infections (e.g. hepatitis B), or malignancy.
  Idiopathic MN has a variable natural course. Although spontaneous remission of NS oc-
curs in about one third of patients   [3]  , end-stage renal failure is observed in about 40% of 
patients after 10 years   [4]  . Many patients with MN are treated by conservative therapy with 
renin-angiotensin system blockade. If partial (PR) or complete remission (CR) is not achieved 
after 6–12 months, therapy based on steroids and immunosuppressant drugs, such as alkyl-
ating agents, calcineurin inhibitors, and mycophenolate mofetil, is considered. Indications 
for treatment and choice of drugs remain debated because these therapies carry the risk of 
severe toxic effects, and despite their use for 30 years, controversy still remains about the bal-
ance between benefits and safety   [5, 6]  . Therefore, the development of well-tolerated and ef-
ficient pathophysiology-driven therapy is needed.
    In the past decade, two major events have occurred. One is the identification of target 
antigens in human MN. The first is neutral endopeptidase, an alloantigen involved in neo-
natal MN, found in newborns from mothers deficient in this endopeptidase   [7]  . The second 
is the M-type phospholipase A  2  receptor (PLA  2  R), the first autoantigen identified in idio-
pathic MN in adults   [8]  . Aldose reductase and superoxide dismutase were identified more 
recently   [9]  . These findings open new perspectives in the monitoring and treatment of the 
disease. The second event is the emergence of rituximab as a potential treatment option for 
MN. Rituximab is an antibody directed against the B-cell antigen CD20. Because B-cell ac-
tivation is a key step in the pathogenesis of MN, rituximab represents a first step toward spe-
cific therapy   [10, 11]  . Its use was first reported by Remuzzi et al.   [12]   in a pilot study, and 
follow-up studies were subsequently published by Remuzzi and Fervenza’s groups. However, 
these studies were uncontrolled and non-randomized  [12–17] . A systematic review about the 
use of rituximab for MN was performed by Bomback et al.  [18]  in 2009. Rituximab, at a dose 
of 375 mg/m  2   once weekly for 1–4 weeks, or of 1 g on days 1 and 15, achieved a 10–20% rate 
of CR and a 40–60% rate of PR at 12 months, which is much more than expected spontane-
ously. In contrast to classical immunosuppressants, modest side effects and no major adverse 
events were observed. Though initial results were promising, further studies are needed to 
confirm the efficacy and safety of rituximab in MN.
    We conducted a retrospective study in 8 French nephrology centers aimed to establish 
the rate of remission and to identify factors associated with remission in patients treated with 
rituximab for idiopathic MN. This clinical study was supplemented with an immunopatho-
logical study in 10 patients.3
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  Patients  and  Methods 
 Patients 
  All renal pathology records of renal biopsies and pharmacological records of rituximab 
prescription were reviewed over a 6-year period in 8 French nephrology centers to identify 
patients with idiopathic MN treated with rituximab. A total of 40 patients were identified 
from October 2005 to October 2009. Twenty-eight patients were included (6 women and 22 
men). All of them were nephrotic and treated with angiotensin-converting enzyme inhibitors 
(ACEI) or angiotensin receptor blockers (ARB) for various periods of time prior to the initia-
tion of rituximab. Twelve patients were excluded, including 4 patients with missing data, 2 
patients with long-term calcineurin inhibitor dependence who were already in CR at the ini-
tiation of rituximab, and 6 patients with MN complicated by systemic lupus erythematosus. 
Clinical data (medians and ranges) were obtained by review of patient records and included 
age, gender, height, weight, blood pressure, date of renal biopsy, previous treatment and con-
comitant immunosuppressive therapy, time and dose of rituximab and follow-up at 3, 6 and 
(if available) 12 months. We collected the data of urinary protein excretion, serum albumin, 
serum creatinine and estimated glomerular filtration rate (eGFR) by the MDRD formula be-
fore the initial renal biopsy, at initiation of rituximab treatment, and 3, 6 and (when available) 
12 months after the first infusion. The stage of MN was also recorded if available.
  Immunopathological  Study 
 Circulating antibodies were assessed by a direct immunofluorescence assay with the use 
of human embryonic kidney 293 (HEK293) cells that were transiently transfected with full-
length complementary DNA encoding a PLA  2  R1 isoform (Euroimmun AG, Lübeck, Ger-
many), as previously described   [19]  . PLA  2  R in immune deposits was assessed by confocal 
microscopy in paraffin blocks with affinity-purified specific anti-PLA  2 R  antibodies  (Atlas 
antibodies)   [19] .
  Statistical  Analysis 
  All continuous variables were expressed as medians and interquartile ranges. The out-
come evaluated in this study included serum creatinine, serum albumin and proteinuria 
rates at 3, 6 and 12 months. CR was defined as proteinuria   !  0.5 g/day (or protein:creatinine 
ratio  ! 500 mg/mg) with stable renal function, and PR was defined as proteinuria  ! 3.5 g/day 
(or protein:creatinine ratio   !  3,500 mg/mg), reduction in proteinuria   1  50% and proteinuria 
  6  0.5 g/day (or protein:creatinine ratio   6  500 mg/mg) with stable renal function. Low re-
sponse (LR) was defined as a reduction  1 50% of the basal level of proteinuria and proteinuria 
  1  3.5 g/day (or protein:creatinine ratio   1  3,500 mg/mg) with stable renal function. Treatment 
success was considered in two different ways, first reaching a CR or PR, and second reaching 
CR, PR or LR. Values at baseline, and 3, 6 and 12 months were compared using Fischer’s ex-
act test. For multivariate analysis, two-way analysis of variance was performed to determine 
the effect of age and chronic renal disease on response. The statistical significance level was 
defined as p   !   0.05.
  R e s u l t s  
 Patient  Characteristics 
  Twenty-eight patients (6 women and 22 men) with biopsy-proven MN and nephrotic 
syndrome (median age 44.4 years, range 18.5–82.4) were identified as presumed idiopathic 
MN (  table 1  ). Twenty patients had stage 2 MN and 8 patients stage 1 MN. Time from renal 4
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biopsy to the beginning of treatment with rituximab was 15 months (range: 0.6–76). Eight 
patients had failed previous immunosuppressive treatment: 1 patient with prednisone alone 
before treatment with rituximab, 2 patients with prednisone and a cytotoxic agent [(cyclo-
phosphamide (n = 1) and chlorambucil (n = 1)], 3 patients with calcineurin inhibitors (1 of 
them with a cytotoxic agent after failure of calcineurin inhibitor treatment) and 2 patients 
with mycophenolate mofetil and prednisone. The 20 remaining patients had received ritu-
ximab as first-line immunosuppressive treatment. Two of them were treated with other im-
munosuppressants combined with rituximab (including 1 receiving tacrolimus and 1 receiv-
ing prednisone). The 28 patients were all on ACEI or ARB at initiation of rituximab therapy 
although the duration of prior treatment was variable. The median time of treatment with 
ACEI/ARB was 14 months, but 1 patient was treated only for 2 weeks and 1 patient for almost 
74 months.
    Rituximab treatment differed among hospitals. It was administered weekly at a dose of 
375 mg/m  2   of body surface area for 4 weeks in 13 patients, for 3 weeks in 3 patients, and for 
2 weeks in 11 patients. Moreover, 1 patient received 2 infusions at a dose of 1,000 mg on days 
1 and 15. No patient received an additional infusion of rituximab after 6 or 12 months.
  Global  Renal  Outcome 
 Median follow-up lasted 11.9 months (range 6–50), and every patient was followed up for 
at least 6 months. The protein:creatinine ratio decreased from 6,230 (1,780–21,022) to 3,070 
mg/mg (160–14,445; p   !   0.00005, paired t test) 6 months after rituximab treatment (n = 28) 
and to 828 mg/mg (53–16,465) 12 months after rituximab treatment (n = 23;   table 2  ;   fig. 1  ). 
Table 1.   Factors at baseline associated with renal PR or CR at 6 or 12 months
All patients
(n = 28)
Remission 
(n = 22)
No remission
(n = 6)
Demographics
Age, years
Male gender
44.4 (18.5–82.4)
22 (78.6%)
43.8 (19.5–78.6)
19 (86.4%)
57.7 (18.5–82.4)
3 (50%)
Previous immunosuppression
ACEI/ARB before rituximab, months
8 (28.6%)
14.0 (0.5–74)
7 (32%)
14.5 (0.5–74)
1 (17%)
13.2 (4.6–30.1)
Rituximab infusion protocol
375 mg/m2 weekly !2
375 mg/m2 weekly !3
375 mg/m2 weekly !4
1,000 mg days 1 and 15
11 (39%)
3 (11%)
13 (46.5%)
1 (3.5%)
8 (36%)
3 (14%)
11 (50%)
0
3 (50%)
0
2 (33.3%)
1 (16.7%)
Clinical parameters
Body weight, kg
Systolic blood pressure, mm Hg
Diastolic blood pressure, mm Hg
76 (44.9–127)
127.5 (100.0–159.0)
76 (57.0–97.0)
76.2 (56.0–95.0)
127.5 (100.0–150.0)
73.5 (57.0–97.0)
67.5 (44.9–127)
130.5 (124.0–159.0)
80.0 (66.0–93.0)
Laboratory parameters
Serum creatinine, mol/l
eGFR, ml/min/1.73 m2
Serum albumin, g/dl
Protein:creatinine ratio, mg/mg
110.5 (43–231)
68.7 (18.8–162.6)
1.9 (0.9–3.5)
6,230 (1,780–21,021)
106 (43–231)*
75.5 (18.8–162.6)
2.0 (1.1–3.5)
6,230 (1,780–21,021)
141 (76–224)
38.0 (33.5–122)*
1.6 (0.9–2.4)
7,200 (4,040–13,216)
D  ata are medians (ranges). * p < 0.05 vs. without remission.5
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In the meantime, serum creatinine remained stable (  fig. 2  ) and serum albumin increased 
from 1.9 (0.9–3.5) to 3.0 g/dl (2.0–4.4; p   !   0.0005, paired t test) after 6 months and 3.7 g/dl 
(2.0–4.5; p  !  0.00005, paired t test) after 12 months ( table 2 ;  fig. 3 ). Six months after the ritu-
ximab treatment, CR was achieved in 2 patients and PR in 12 patients, corresponding to an 
overall remission rate of 50%. Three additional patients achieved LR. The overall renal re-
sponse rate including CR, PR and LR was 60.7%.
  Twelve months after rituximab treatment (n = 23), CR was achieved in 6 patients and PR 
in 13 patients, corresponding to an overall renal response of 82.6%. No patient had LR at 12 
months. The median decrease in proteinuria over creatinine ratio was 62.3% at 6 months 
(–65.3 to 96.8) and 86.8% (–80.3 to 99) at 12 months. Among the 12 patients with PR at 6 
months, 4 achieved CR at 12 months, 6 maintained PR at 12 months and follow-up data are 
Table 2. Main clinical and laboratory parameters in the 28 study patients with idiopathic MN from rituximab initiation 
(baseline) to the 12-month follow-up
Baseline (n = 28) 3 months (n = 28) 6 months (n = 28) 12 months (n = 23)
Systolic BP, mm Hg
Diastolic BP, mm Hg
Serum creatinine, mol/l
eGFR, ml/min/1.73 m2
Serum albumin, g/dl
Protein:creatinine ratio, mg/mg
127.5 (100–159)
76 (57–97)
110.5 (43–231)
68.7 (18.8–162.6)
1.9 (0.9–3.5)
6,230 (1,780–21,021)
125.0 (96–164)
75.0 (54–87)
115 (65–212)
70 (28.3–141.1)
2.7 (1.0–3.9)a
3,827 (445–13,804)b
120.0 (90–170 )
70.0 (52–100)
105 (53–204)
72.6 (29.5–164.9)
3.0 (2.0–4.4)c
3,070 (160–14,445)c
123.0 (90–176)
75.0 (60–107)
111 (65–199)
61.8 (6–119)
3.7 (2.0–4.5)c
828 (53–16,465)b
D  ata are medians (ranges). BP = Blood pressure. a p < 0.005; b p < 0.0005; c p < 0.00005, vs. baseline.
  Fig. 1.   The protein:creatinine ratio from baseline 
(month 0) up to the 12-month follow-up in patients 
who were treated with rituximab. Medians   8  
SEM. 
  Fig. 2.   Serum    creatinine from baseline (month 0) 
up to the 12-month follow-up in patients who were 
treated with rituximab. Medians   8   SEM. 6
Nephron Extra 2011;1:251–261 
 DOI:  10.1159/000333068 
EXTRA
  Michel et al.: Rituximab in Membranous Nephropathy  
www.karger.com/nne
    © 2011 S. Karger AG, Basel
  Published online: December 24, 2011 
lacking for 2 patients. Among the 2 patients with CR at 6 months, 1 maintained CR and fol-
low-up data are not available for 1 patient. Among the 3 patients with LR at 6 months, 2 pa-
tients achieved PR and data are missing for 1 patient. Of note, among the 11 patients who 
showed no response at 6 months, 1 achieved CR at 12 months, 5 achieved PR at 12 months, 
4 showed no response and follow-up data are lacking for 1 patient (  fig. 4  ).
  During the follow-up, 3 patients relapsed 27, 39 and 50 months after the initial rituximab 
treatment, respectively. Two of them were retreated with rituximab. The 1st patient experi-
enced a relapse (proteinuria 6.8 g/day) 50 months after the first rituximab treatment. He was 
retreated with rituximab 375 mg/m  2   weekly for 2 weeks. Six months later, proteinuria de-
creased to 0.7 g/day and serum albumin increased from 2.9 to 3.7 g/dl. The 2nd patient ex-
perienced a relapse 39 months after the initial rituximab treatment. Treatment with ritux-
imab was resumed at 375 mg/m 2  weekly for 2 weeks. Three months later the protein:creatinine 
ratio decreased from 5,162 to 3,560 mg/mg and serum albumin increased from 2.2 to 3.1 
g/dl.
    Factors Predicting Renal Response 
 Univariate  Analysis 
  Response rates (CR and PR) were significantly associated with MDRD eGFR   1 45  ml/
min/1.73 m  2  (p = 0.02). Age  1 60 years and female gender were associated with lower response 
rates (p = 0.05 and p = 0.05). However, response rates were not associated with previous im-
munosuppressive treatment or treatment dosage (  table 3  ). The patients who did not respond 
to rituximab tended to have more proteinuria [protein:creatinine ratio 7,200 mg/mg (4,040–
13,216)] and lower serum albumin [1.6 g/dl (0.9–2.4)] than those who responded to rituximab 
[(protein:creatinine ratio 6,230 mg/mg (1,780–21,021) and serum albumin 2.0 g/dl (1.1–3.5)], 
  Fig. 3.   Serum albumin from baseline (month 0) up 
to the 12-month follow-up in patients who were 
treated with rituximab. Medians   8   SEM. 
  Fig. 4.   Response 12 months after rituximab treat-
men t in th e 1 1 pa ti en ts wi th n o respo nse (NR ) , 
2 with LR, 12 with PR and 2 patients with CR at 
6 months. NA = Not available. 7
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but the difference did not reach statistical significance (p = 0.32 for proteinuria and 0.52 for 
the serum albumin).
  M u l t i v a r i a t e   A n a l y s i s  
  In multivariate analysis, MDRD eGFR   1  45 ml/min/1.73 m  2   was associated with a high-
er response rate (CR and PR), with an odds ratio (OR) of 8.08 and a 95% confidence interval 
(CI) of 0.8–86.1, but no significant difference was found (p = 0.08). For age   ! 60  years,  OR 
was 1.70 (95% CI 0.1–21.3) and for male gender, OR was 3.7 (95% CI 0.4–39.3).
  B-Cell  Depletion 
  In 10 patients, B-cell depletion was complete 1 month after rituximab infusion (CD19 
lymphocytes   !  1%), while data were lacking for the 18 other patients. Remission occurred in 
70% of the patients with CD19 monitoring and in 83.3% of the remainder (p = 0.46).
  Immunopathological  Study 
  In this retrospective study, anti-PLA  2  R autoantibodies could be assessed     in 10 patients, 
all from the Department of Nephrology at the Tenon Hospital in Paris. Sera were sampled at 
the time of biopsy before rituximab treatment. Follow-up sera were available in 5 patients, 
including 3 patients with iterative samples. Search for PLA  2  R in immune deposits was per-
formed in 9 of the patients.
  A n t i - P L A  2  R autoantibodies were found in the serum of the 10 patients but at variable 
titers before rituximab treatment ( table 4 ). Search for PLA  2 R antigen in immune deposits was 
strongly positive in 5 patients, weakly positive in 2 patients, very weakly positive in 1 patient 
and negative in 1 patient (  table 4  ). Interestingly, 1 patient (patient 7) with very high titer of 
anti-PLA  2  R antibody had no PLA  2  R detectable in immune deposits.
Remission 
(n = 22)
No remission 
(n = 6)
p
value
Demographics
Age
<60 years
>60 years
Gender
Male
Female
19
3
19
3
3
3
3
3
0.05
0.05
Protocol of rituximab infusion
Low dose1
High dose2
8
14
2
4
1.0
Laboratory parameters
eGFR 0.02*
<45 ml/min/1.73 m2 34
>45 ml/min/1.73 m2 19 2
Proteinuria/creatininuria 1.0
<10,000 mg/mg
>10,000 mg/mg
15
7
4
2
1  Two infusions of rituximab weekly at a dose of 375 mg/m2.
2 Three or 4 infusions of rituximab weekly at a dose of 375 mg/m2 
or 1,000 mg on days 1 and 15.
Table 3.   Factors associated with 
renal PR or CR at 6 or 12 
months (univariate analysis)8
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    PR or CR was associated with disappearance of anti-PLA  2  R antibodies in all patients. 
Disappearance of anti-PLA  2  R autoantibodies was noted 5–48 months after initiation of 
rituximab therapy, but kinetics could not be established in the absence of early samples.
    One patient had a relapse in the absence of detectable anti-PLA  2  R antibody (patient 9).
  Adverse  Events 
 Screening for adverse events during rituximab treatment was not exhaustive. Rituximab 
was generally well tolerated. The few reported side effects were typically mild, transient, and 
thought to be due to infusion; no serious adverse events were reported.
  Discussion 
 In this first French multicenter retrospective study, we analyzed the clinical course of 28 
proteinuric patients with idiopathic MN. Four important observations were made. First, 
rituximab appears to be effective in reducing proteinuria in the majority of patients. Second, 
the reduction in proteinuria was gradual, with 3 of the 9 non-responders after 6 months 
achieving remission after 12 months (  fig. 4  ). Third, the only parameter that seems to be as-
sociated with rituximab response is the initial level of renal function. Fourth, anti-PLA  2 R 
autoantibodies were detected in all 10 patients studied and became negative after rituximab 
therapy in all 5 patients with available follow-up sera.
    In our series, remission rates were 50 and 82.6% at 6 and 12 months, respectively, being 
apparently superior to those published by Cravedi et al.  [14] , Fervenza et al.  [16, 17]  and oth-
ers   [12, 13, 15]  , who reported global remission rates at 12 months of 65 and 60%, respec-
tively. Several potential confounding factors should be discussed. First, given the heteroge-
neous course of the disease and the absence of a control group, we cannot rule out that part 
of the beneficial effect observed was due to spontaneous remission rather than to a thera-
peutic effect of rituximab. Indeed, the rate of spontaneous remission averages at 30%   [3, 4]  . 
However, although the majority of spontaneous remissions occurs within the first 2 years 
after initial presentation, we did not find an association between response to rituximab and 
the duration of MN before treatment [mean duration 14.5 months (range: 0.6–76.6) in re-
Table 4.   Assessment of anti-PLA2R autoantibodies in the serum, PLA2R in the biopsy and response at 12 
months in 10 of the 28 patients
Patients PLA2R in
immune deposits
A nti-PLA2R autoantibodies in the serum Response at
12 months before treatment after treatment
1 positive 1:100 not available CR
2 positive 1:1,000 not available PR
3 positive 1:320 negative CR
4 positive 1:100 negative PR
5 weakly positive 1:320 negative PR
6 positive 1:320 not available no response
7 negative 1:3,200 1:1,0001 PR
8 very weakly positive 1:320 not available PR
9 weakly positive 1:10 negative CR
10 not available 1:10 negative PR
1 E  arly sampling at 4 weeks (no additional follow-up sample).9
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sponders versus 13.2 months (range 4.6–30.1) in non-responders]. Second, 9 patients were 
given rituximab before completion of a 6-month conservative therapy with ACE/ARB, how-
ever we did not observe a greater reduction in proteinuria in those patients treated with 
ACE/ARB during   !  6 months (data not shown). Third, at 12 months, 5 of 28 patients (18%) 
were lost to follow-up. Although these 5 patients showed a remission rate of 60% (1 CR and 
2 PR) at 6 months, which was superior to that observed in the other patients, we cannot rule 
out an overestimation of the response to rituximab at 1 year. Fourth, 1 patient received 
rituximab despite proteinuria levels below the nephrotic range (protein:creatinine ratio: 
1,780 mg/mg; serum albumin: 1.8 g/dl) and had CR at 12 months, which contributed to the 
particularly favorable response to rituximab observed in our patients. Fifth, 1 patient re-
ceived tacrolimus with rituximab and had PR, which may be closer associated with tacroli-
mus than rituximab treatment.
    Our univariate and multivariate analyses suggest that creatinine is an independent fac-
tor which is negatively correlated with the response to rituximab after 6 months. This sup-
ports previous findings indicating that poor renal function and tubulointerstitial changes 
predict a poor response to rituximab   [15, 16]  . Although a higher rate of remission was ob-
served in patients with lower basal proteinuria by Fervenza et al.   [16]  , proteinuria did not 
significantly differ in our patients whether or not they achieved remission after 6 months. 
We observed only a trend toward higher proteinuria in the patients without response, which 
might be due to the small number of patients in our study cohort. However, the apparent 
lower response rate in patients with higher basal proteinuria in the study by Fervenza et al.   
[16]   may also be related to a delay in the efficacy of rituximab. This hypothesis is supported 
by the observation that in their series, mean serum albumin had approached normal levels 
(3.5   8   0.8 g/dl) at 12 months while mean urinary protein excretion was still within the ne-
phrotic range (6.0 g/day).
  Because high-grade proteinuria leads to losses of rituximab in the urine and a shortened 
half-life of the antibody, Fervenza et al.   [16]       postulated that high-dose rituximab could re-
sult in a higher remission rate while maintaining a similar safety profile although no cor-
relation was found between rituximab levels and the degree of proteinuria or response rates 
  [16, 17]  . We did not observe either a higher rate of CD19 depletion or a better clinical re-
sponse in patients treated with high-dose rituximab (3–4 infusions of rituximab weekly at 
a dose of 375 mg/m  2   or 2 infusions of 1,000 mg on days 1 and 15) compared to patients 
treated with low-dose rituximab (2 weekly infusions at a dose of 375 mg/m  2  ). The median 
decrease in proteinuria over creatinine ratio from baseline was 62 and 87% at 6 months and 
12 months, respectively, in patients treated with a high dose (n = 18), and 61 and 86% at 6 
and 12 months, respectively, in patients given a low dose (n = 10; p = 0.67 and 0.54 at 6 
months and 12 months, respectively). These results support previous titration data suggest-
ing that 1–2 weekly infusions of 375 mg/m  2  are enough to achieve complete B-cell depletion 
and that a larger dose of rituximab does not provide additional benefits in terms of protein-
uria reduction rate   [14]  .
  A n t i - P L A  2  R autoantibodies were detected in all of the 10 study patients, and PLA  2 R  an-
tigen was found in immune deposits in 8 of the 9 available biopsies. In the initial report by 
Beck et al.   [8]  , the prevalence of anti-PLA  2  R autoantibody was 70%. In a recent study of 42 
consecutive patients with biopsy-proven idiopathic MN  [20] , we reported a lower prevalence 
of 57% positive sera and 74% positive biopsies compared to the present study, which might 
be due to the size of the sample. One patient had high-titer autoantibodies but no PLA  2 R  in 
deposits, which might suggest that antibodies were not nephritogenic or that epitopes were 
poorly accessible at the time of kidney biopsy.
  A n t i - P L A  2  R autoantibodies disappeared under rituximab treatment in the 5 patients 
with follow-up sera. There was apparently no correlation between the titer of anti-PLA  2 R 10
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autoantibody at the time of initiation of rituximab therapy and the quality (CR or PR) of the 
response to the drug. The only patient (No. 6) with no response had high-titer anti-PLA  2 R 
autoantibody. In the patient who relapsed in the absence of anti-PLA  2  R antibody (No. 9), 
antibodies directed against other antigenic specificities might be involved. Because of the 
high rate of efficacy of rituximab and the small sample size, it was not possible to establish 
a correlation between anti-PLA  2  R autoantibodies and clinical response although this was 
previously suggested by preliminary studies from Beck and Salant   [21]  .
    Our study has important limitations inherent to its retrospective design. The follow-up 
before and after rituximab administration, the duration of ACEI/ARB treatment and the 
protocol of rituximab treatment were heterogeneous. However, this kind of study mirrors 
real practices in the absence of guidelines for rituximab treatment.
    In conclusion, rituximab appears to be effective in achieving CR or PR (82.6%) in pro-
teinuric patients at 12 months. Despite accumulating evidence in favor of the efficacy of 
rituximab from our study data and the previous literature, no definitive conclusion can be 
drawn. An adequately powered, randomized clinical trial is now needed to assess the benefit-
risk profile of rituximab in idiopathic MN as well as the response of anti-PLA  2 R  antibodies 
to therapy.
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